6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
=2 O
% O
) O
reported O
in O
IBS-C O
or O
CIC O
patients O
are O
: O
diarrhea O
, O
abdominal O
pain O
, O
flatulence O
and O
abdominal O
distension O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Allergan O
at O
1-800-678-1605 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Exposure O
in O
clinical O
development O
included O
approximately O
2570 O
, O
2040 O
, O
and O
1220 O
patients O
with O
either O
IBS-C O
or O
CIC O
treated O
with O
LINZESS O
for O
6 O
months O
or O
longer O
, O
1 O
year O
or O
longer O
, O
and O
18 O
months O
or O
longer O
, O
respectively O
( O
not O
mutually O
exclusive O
) O
. O

Demographic O
characteristics O
were O
comparable O
between O
treatment O
groups O
in O
all O
studies O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Irritable O
Bowel O
Syndrome O
with O
Constipation O
( O
IBS-C O
) O
Most O
Common O
Adverse O
Reactions O
The O
data O
described O
below O
reflect O
exposure O
to O
LINZESS O
in O
the O
two O
placebo-controlled O
clinical O
trials O
involving O
1605 O
adult O
patients O
with O
IBS B-Not_AE_Candidate
- I-Not_AE_Candidate
C I-Not_AE_Candidate
( O
Trials O
1 O
and O
2 O
) O
. O

Patients O
were O
randomized O
to O
receive O
placebo O
or O
290 O
mcg O
LINZESS O
once O
daily O
on O
an O
empty O
stomach O
for O
up O
to O
26 O
weeks O
. O

Table O
1 O
provides O
the O
incidence O
of O
adverse O
reactions O
reported O
in O
at O
least O
2 O
% O
of O
IBS-C O
patients O
in O
the O
LINZESS O
treatment O
group O
and O
at O
an O
incidence O
that O
was O
greater O
than O
in O
the O
placebo O
group O
. O

Table O
1 O
: O
Most O
Common O
Adverse O
Reactionsa O
in O
Two O
Placebo-Controlled O
Trials O
( O
1 O
and O
2 O
) O
in O
Patients O
with O
IBS-C O
a O
: O
Reported O
in O
at O
least O
2 O
% O
of O
LINZESS-treated O
patients O
and O
at O
an O
incidence O
greater O
than O
placebo O
b O
: O
`` O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
`` O
term O
includes O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
lower B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

Adverse O
Reactions O
LINZESS O
290 O
mcg O
[ O
N=807 O
] O
% O
Placebo O
[ O
N=798 O
] O
% O
Gastrointestinal B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
b O
Flatulence B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
20742 O
3521 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Viral B-OSE_Labeled_AE
Gastroenteritis I-OSE_Labeled_AE
3 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
4 O
3 O
Diarrhea O
Diarrhea B-OSE_Labeled_AE
was O
the O
most O
commonly O
reported O
adverse O
reaction O
of O
the O
LINZESS-treated O
patients O
in O
the O
pooled O
IBS B-Not_AE_Candidate
- I-Not_AE_Candidate
C I-Not_AE_Candidate
pivotal O
placebo-controlled O
trials O
. O

In O
these O
trials O
, O
20 O
% O
of O
LINZESS-treated O
patients O
reported O
diarrhea B-OSE_Labeled_AE
compared O
to O
3 O
% O
of O
placebo-treated O
patients O
. O

Severe O
diarrhea B-OSE_Labeled_AE
was O
reported O
in O
2 O
% O
of O
the O
LINZESS-treated O
patients O
versus O
less O
than O
1 O
% O
of O
the O
placebo-treated O
patients O
, O
and O
5 O
% O
of O
LINZESS-treated O
patients O
discontinued O
due O
to O
diarrhea B-OSE_Labeled_AE
vs O
less O
than O
1 O
% O
of O
placebo-treated O
patients O
. O

The O
majority O
of O
reported O
cases O
of O
diarrhea B-OSE_Labeled_AE
started O
within O
the O
first O
2 O
weeks O
of O
LINZESS O
treatment O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Adverse O
Reactions O
Leading O
to O
Discontinuation O
In O
placebo-controlled O
trials O
in O
patients O
with O
IBS B-Not_AE_Candidate
- I-Not_AE_Candidate
C I-Not_AE_Candidate
, O
9 O
% O
of O
patients O
treated O
with O
LINZESS O
and O
3 O
% O
of O
patients O
treated O
with O
placebo O
discontinued O
prematurely O
due O
to O
adverse O
reactions O
. O

In O
the O
LINZESS O
treatment O
group O
, O
the O
most O
common O
reasons O
for O
discontinuation O
due O
to O
adverse O
reactions O
were O
diarrhea B-OSE_Labeled_AE
( O
5 O
% O
) O
and O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
1 O
% O
) O
. O

In O
comparison O
, O
less O
than O
1 O
% O
of O
patients O
in O
the O
placebo O
group O
withdrew O
due O
to O
diarrhea B-NonOSE_AE
or O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
. O

Adverse O
Reactions O
Leading O
to O
Dose O
Reductions O
In O
the O
open-label O
, O
long-term O
trials O
, O
2147 O
patients O
with O
IBS B-Not_AE_Candidate
- I-Not_AE_Candidate
C I-Not_AE_Candidate
received O
290 O
mcg O
of O
LINZESS O
daily O
for O
up O
to O
18 O
months O
. O

In O
these O
trials O
, O
29 O
% O
of O
patients O
had O
their O
dose O
reduced O
or O
suspended O
secondary O
to O
adverse O
reactions O
, O
the O
majority O
of O
which O
were O
diarrhea B-OSE_Labeled_AE
or O
other O
GI B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Less O
Common O
Adverse O
Reactions O
Defecation B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
and O
gastroesophagal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
were O
reported O
in O
< O
2 O
% O
of O
patients O
in O
the O
LINZESS O
treatment O
group O
and O
at O
an O
incidence O
greater O
than O
in O
the O
placebo O
treatment O
group O
. O

Chronic O
Idiopathic O
Constipation O
( O
CIC O
) O
Most O
Common O
Adverse O
Reactions O
The O
data O
described O
below O
reflect O
exposure O
to O
LINZESS O
in O
the O
two O
double-blind O
placebo-controlled O
clinical O
trials O
of O
1275 O
adult O
patients O
with O
CIC B-Not_AE_Candidate
( O
Trials O
3 O
and O
4 O
) O
. O

Patients O
were O
randomized O
to O
receive O
placebo O
or O
145 O
mcg O
LINZESS O
or O
290 O
mcg O
LINZESS O
once O
daily O
on O
an O
empty O
stomach O
, O
for O
at O
least O
12 O
weeks O
. O

Table O
2 O
provides O
the O
incidence O
of O
adverse O
reactions O
reported O
in O
at O
least O
2 O
% O
of O
CIC O
patients O
in O
the O
145 O
mcg O
LINZESS O
treatment O
group O
and O
at O
an O
incidence O
that O
was O
greater O
than O
in O
the O
placebo O
treatment O
group O
. O

Table O
2 O
: O
Most O
Common O
Adverse O
Reactionsa O
in O
the O
Two O
Placebo-controlled O
Trials O
( O
3 O
and O
4 O
) O
in O
Patients O
with O
CIC O
a O
: O
Reported O
in O
at O
least O
2 O
% O
of O
LINZESS-treated O
patients O
and O
at O
an O
incidence O
greater O
than O
placebo O
b O
: O
`` O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
`` O
term O
includes O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
lower B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

Adverse O
Reactions O
LINZESS O
145 O
mcg O
[ O
N=430 O
] O
% O
Placebo O
[ O
N=423 O
] O
% O
Gastrointestinal B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
b O
Flatulence B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
16763 O
5652 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
Sinusitis B-OSE_Labeled_AE
53 O
42 O
The O
safety O
of O
a O
72 O
mcg O
dose O
was O
evaluated O
in O
an O
additional O
placebo-controlled O
trial O
in O
which O
1223 O
patients O
were O
randomized O
to O
LINZESS O
72 O
mcg O
, O
145 O
mcg O
, O
or O
placebo O
once O
daily O
for O
12 O
weeks O
( O
Trial O
5 O
) O
. O

In O
Trial O
5 O
, O
adverse O
reactions O
that O
occurred O
at O
a O
frequency O
of O
> O
= O
2 O
% O
in O
LINZESS-treated O
patients O
( O
n=411 O
in O
each O
LINZESS O
72 O
mcg O
and O
145 O
mcg O
group O
) O
and O
at O
a O
higher O
rate O
than O
placebo O
( O
n=401 O
) O
were O
: O
* O
Diarrhea B-OSE_Labeled_AE
( O
LINZESS O
72 O
mcg O
19 O
% O
; O
LINZESS O
145 O
mcg O
22 O
% O
; O
placebo O
7 O
% O
) O
* O
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
( O
LINZESS O
72 O
mcg O
2 O
% O
; O
LINZESS O
145 O
mcg O
1 O
% O
; O
placebo O
< O
1 O
% O
) O
Diarrhea B-OSE_Labeled_AE
This O
section O
summarizes O
information O
from O
Trials O
3 O
and O
4 O
( O
pooled O
) O
and O
Trial O
5 O
regarding O
diarrhea B-OSE_Labeled_AE
, O
the O
most O
commonly O
reported O
adverse O
reaction O
reported O
in O
LINZESS-treated O
patients O
in O
CIC B-Not_AE_Candidate
placebo-controlled O
studies O
. O

In O
all O
trials O
, O
the O
majority O
of O
reported O
cases O
of O
diarrhea B-OSE_Labeled_AE
started O
within O
the O
first O
2 O
weeks O
of O
LINZESS O
treatment O
. O

Severe O
diarrhea B-OSE_Labeled_AE
was O
reported O
in O
less O
than O
1 O
% O
of O
the O
72 O
mcg O
LINZESS-treated O
patients O
( O
Trial O
5 O
) O
, O
in O
2 O
% O
of O
the O
145 O
mcg O
LINZESS-treated O
patients O
( O
Trials O
3 O
and O
4 O
; O
Trial O
5 O
) O
, O
and O
less O
than O
1 O
% O
of O
the O
placebo-treated O
patients O
( O
Trials O
3 O
, O
4 O
, O
and O
5 O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Adverse O
Reactions O
Leading O
to O
Discontinuation O
In O
placebo-controlled O
trials O
in O
patients O
with O
CIC B-Not_AE_Candidate
, O
3 O
% O
of O
patients O
treated O
with O
72 O
mcg O
( O
Trial O
5 O
) O
and O
between O
5 O
% O
( O
Trial O
5 O
) O
and O
8 O
% O
( O
Trials O
3 O
and O
4 O
) O
of O
patients O
treated O
with O
145 O
mcg O
of O
LINZESS O
discontinued O
prematurely O
due O
to O
adverse O
reactions O
compared O
to O
between O
less O
than O
1 O
% O
( O
Trial O
5 O
) O
and O
4 O
% O
( O
Trials O
3 O
and O
4 O
) O
of O
patients O
treated O
with O
placebo O
. O

In O
patients O
treated O
with O
72 O
mcg O
LINZESS O
the O
most O
common O
reason O
for O
discontinuation O
due O
to O
adverse O
reactions O
was O
diarrhea B-OSE_Labeled_AE
( O
2 O
% O
in O
Trial O
5 O
) O
and O
in O
patients O
treated O
with O
145 O
mcg O
LINZESS O
, O
the O
most O
common O
reasons O
for O
discontinuation O
due O
to O
adverse O
reactions O
were O
diarrhea B-OSE_Labeled_AE
( O
3 O
% O
in O
Trial O
5 O
and O
5 O
% O
in O
Trials O
3 O
and O
4 O
) O
and O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
1 O
% O
in O
Trials O
3 O
and O
4 O
) O
. O

In O
comparison O
, O
less O
than O
1 O
% O
of O
patients O
in O
the O
placebo O
group O
withdrew O
due O
to O
diarrhea B-NonOSE_AE
or O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
( O
Trials O
3 O
and O
4 O
; O
Trial O
5 O
) O
. O

Adverse O
Reactions O
Leading O
to O
Dose O
Reductions O
In O
the O
open-label O
, O
long-term O
trials O
, O
1129 O
patients O
with O
CIC B-Not_AE_Candidate
received O
290 O
mcg O
of O
LINZESS O
daily O
for O
up O
to O
18 O
months O
. O

In O
these O
trials O
, O
27 O
% O
of O
patients O
had O
their O
dose O
reduced O
or O
suspended O
secondary O
to O
adverse O
reactions O
, O
the O
majority O
of O
which O
were O
diarrhea B-OSE_Labeled_AE
or O
other O
GI B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Less O
Common O
Adverse O
Reactions O
Defecation B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
and O
viral B-OSE_Labeled_AE
gastroenteritis I-OSE_Labeled_AE
, O
were O
reported O
in O
less O
than O
2 O
% O
of O
patients O
in O
the O
LINZESS O
treatment O
group O
and O
at O
an O
incidence O
greater O
than O
placebo O
treatment O
group O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
LINZESS O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Hematochezia B-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
and O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
or O
hives B-OSE_Labeled_AE
. O

